祛湿化瘀颗粒治疗高脂血症的疗效与安全性:随机双盲安慰剂对照试验研究方案
本研究为随机双盲安慰剂对照试验,计划纳入210例高脂血症患者等比例分为祛湿化瘀颗粒组与安慰剂颗粒组,治疗24周。主要结局为低密度脂蛋白胆固醇(LDL-C)从基线至第12周的变化,次要结局包括其他血脂指标、生活质量健康调查及中医证候量表变化,并监测不良事件与安全性。
要点
- 祛湿化瘀颗粒治疗高脂血症的疗效与安全性尚缺乏临床证据,本研究旨在填补该空白。
- 主要结局为LDL-C从基线至第12周的变化,治疗持续24周。
- 计划纳入210例受试者,等比例随机分配至祛湿化瘀颗粒组或安慰剂颗粒组。
核心结论
- 该试验结果将展示祛湿化瘀颗粒治疗高脂血症患者的疗效与安全性。
研究设计与样本
- 本研究为随机、双盲、安慰剂对照试验,计划纳入210例受试者,等比例随机分配至祛湿化瘀颗粒组或安慰剂颗粒组,治疗24周。
- 主要结局为LDL-C从基线至第12周的变化;次要结局为其他血清血脂标志物、生活质量健康调查及中医证候量表的变化。
- 所有相关检测在基线、入组后第12周和第24周进行,并监测和评价不良事件及干预安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperlipidemia has become a common chronic disease worldwide in recent years. Studies have shown that hyperlipidemia patients, especially those with a high level of serum low-density lipoprotein cholesterol (LDL-C), have a significantly higher prevalence of atherosclerosis, leading to coronary heart disease. Previous basic experiments and clinical studies have shown that Qushi Huayu granules (QSHY) reduce blood lipids in patients with non-alcoholic fatty liver disease (NAFLD) accompanied by hyperlipidemia. However, the clinical efficacy of QSHY in patients with hyperlipidemia is still lacking. This study aims to investigate the effect and safety of QSHY for hyperlipidemia. METHODS: This is a randomized, double-blind, placebo-controlled trial. A total of 210 participants will be enrolled and randomized into the QSHY or placebo granules groups in equal proportions, who will receive treatment for 24 weeks. The primary outcome will be the change in LDL-C from baseline to week 12. Secondary outcomes will be changes in other serum lipids markers, life quality measuring health surveys, and traditional Chinese medicine (TCM) pattern scale. All related tests will be measured at baseline, week 12, and week 24 after enrollment. Adverse events and the safety of intervention will be monitored and evaluated. DISCUSSION: We designed a clinical trial of hyperlipidemia management with QSHY, a TCM prescription. The results of this trial will present the efficacy and safety of QSHY in patients with hyperlipidemia. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000034125 . Registered on June 25, 2019.
引用
- Sun Y, Hu N, Chen G, et al. Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2022. PMID: 35109888. doi:10.1186/s13063-022-06031-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。